Immunomedics, Inc. (NASDAQ: IMMU) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Immunomedics, Inc. (IMMU) click here.